^
Association details:
| Biomarker: | EGFR L747_A750>P |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations
Published date:
03/13/2023
Excerpt:
The ex19del L747_A750>P is associated with inferior PFS compared to the common E746_A750del mutation in patients treated with 1L osimertinib.
DOI:
https://doi.org/10.1158/1078-0432.CCR-22-3497
Source:
Title:
Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P.
Published date:
05/26/2022
Excerpt:
For 1L osimertinib...Pts with the common del19 mutation were more likely to achieve PFS > 12 months with 1L osimertinib than those with the L747_A750 > P mutation (Odds Ratio 4.14 (1.41-12.15), p 0.0097)....The del19 mutation L747_A750 > P is associated with inferior PFS compared to the common E746_A750del mutation in pts treated with 1L osimertinib.
DOI:
10.1200/JCO.2022.40.16_suppl.e21112
